SecBot SecBot
8-K ·Filed Aug 11, 2026

COAG

Hemab Therapeutics Holdings, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-343421
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The FDA endorsement for Phase 3 initiation of sutacimig in GT is the most significant catalyst, watch for trial enrollment updates and data readouts in late 2026/early 2027. HMB-002 and HMB-003 data readouts in late 2026/early 2027 are secondary catalysts. The strong cash runway removes near-term financing risk.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$49.87
T+0 close · Aug 11, 2026 · via day close
Latest settled
−12.85%
T+60 · $43.46
Vs SPY
−12.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $49.87entry
  2. T+1 · 3mo ago +7.24%α +6.99% · $53.48
  3. T+5 · 3mo ago +5.15%α +5.56% · $52.44
  4. T+20 · 2mo ago −10.77%α −9.71% · $44.50
  5. T+60 · 13d ago −12.85%α −12.72% · $43.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line with consensus of $-0.82. The company highlighted FDA endorsement to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia, positive Phase 1/2 data for HMB-002 in Von Willebrand Disease, and unveiled a new preclinical program HMB-003. Cash position strengthened to $457.5M post-IPO, providing runway into 2029. The stock will move on pipeline catalysts rather than the pre-revenue financials.

Key Financial Metrics

EPS
−$0.80
est −$0.82 · +2.4%
Rating
in line

Key Facts

  • Net loss of $24.2M ($0.80/share) vs consensus $-0.82, in line
  • Cash, cash equivalents, and marketable securities totaled $457.5M as of June 30, 2026, up from $163.5M at March 31, 2026
  • FDA endorsed clinical data package for sutacimig as sufficient to proceed to Phase 3 pivotal trial in Glanzmann thrombasthenia; Phase 3 initiation planned 2H 2026
  • HMB-002 Phase 1/2 data showed 2.4-fold increase in VWF and FVIII, with 8 of 9 evaluable patients having zero treated bleeds in 28 days
  • Unveiled HMB-003, a novel peptide-based plasmin inhibitor for heavy menstrual bleeding; first-in-human studies planned 2H 2026
  • R&D expenses $20.3M (Q2 2026) vs $12.9M (Q2 2025), reflecting clinical program advancement

Financial Impact

Q2 2026 net loss of $24.2M ($0.80/share) vs consensus $-0.82, in line. Cash runway extended into 2029 with $457.5M post-IPO.

net losscash positionR&D expenses

Risk Factors

  • Phase 3 trial failure or safety signal in sutacimig
  • Competition from existing therapies (recombinant Factor VIIa, platelet transfusions)
  • Dilution risk if additional capital is needed beyond current runway
  • Clinical trial enrollment delays

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-343421
Document: d180684d8k.htm0001193125-26-343421
Document: 0001193125-26-343421-index-headers.html0001193125-26-343421
Document: 0001193125-26-343421-index.html0001193125-26-343421
Document: 0001193125-26-343421.txt0001193125-26-343421
8-K Data (Synthetic)0001193125-26-343421

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Viewing Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 7h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026